Answers are grounded in this paper and cite their sources.
Human papillomaviruses (HPVs) are the etiological agent of a significant, and increasing, fraction of head and neck squamous cell carcinomas (HNSCC)—a heterogenous group of malignancies in the head and neck region. HPV infection accounts for approximately 25% of all cases, with the remainder typically caused by smoking and excessive alcohol consumption. These distinct etiologies lead to profound clinical and immunological differences between HPV‐positive (HPV + ) and HPV‐negative (HPV − ) HNSCC, likely related to the expression of exogenous viral antigens in the HPV + subtype. Specifically, HPV + HNSCC patients generally exhibit better treatment response compared to those with HPV − disease, leading to a more favorable prognosis, with lower recurrence rate, and longer overall survival time. Importantly, a plethora of studies have illustrated that the tumor immune microenvironment (TIME) of HPV + HNSCC has a strikingly distinct immune composition to that of its HPV − counterpart. The HPV + TIME is characterized as being immunologically “hot,” with more immune infiltration, higher levels of T‐cell activation, and higher levels of immunoregulation compared to the more immunologically “cold” HPV − TIME. In general, cancers with an immune “hot” TIME exhibit better treatment response and superior clinical outcomes in comparison to their immune “cold” counterparts. Indeed, this phenomenon has also been observed in HPV + HNSCC patients, highlighting the critical role of the TIME in influencing prognosis, and further validating the use of cancer therapies that capitalize on the mobilization and/or modulation of the TIME. This article is categorized under: Cancer > Molecular and Cellular Physiology Infectious Diseases > Molecular and Cellular Physiology
No takes yet. Share an insight, caveat, or question.
Gameiro et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: